The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The deal isn't cheap; the biotech is changing hands at a 34% premium. It gives the buyer a unique product that was FDA-approved barley over a year ago. 10 stocks we like better than Soleno ...

Soleno Therapeutics plans to offer $200 million in common stock to fund commercialization of VYKAT™ XR and other activities. Soleno Therapeutics, Inc. announced its plan to conduct a public offering ...

Soleno Therapeutics (NASDAQ:SLNO) shares surged 8% on Tuesday after the biopharmaceutical company announced a $100 million accelerated share repurchase (ASR) agreement with Jefferies LLC, underscoring ...

Soleno Therapeutics faces scrutiny after a patient death on Vykat, though both company and physician deem it unrelated to treatment. SLNO's Vykat launch shows strong early revenue and prescriber ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

On August 15, 2025, Scorpion Capital published a report that described Soleno’s only product, Vykat XR, as overpriced and potentially unsafe for children. On this news, the price of Soleno shares ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics. VYKAT XR’s label is highly favorable: broad indication, strong safety profile, no box ...

Detailed price information for Soleno Therapeutics Inc (SLNO-Q) from The Globe and Mail including charting and trades.

Whales with a lot of money to spend have taken a noticeably bullish stance on Soleno Therapeutics. Looking at options history for Soleno Therapeutics (NASDAQ:SLNO) we detected 10 trades. If we ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming May 5, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit ...

Neurocrine Biosciences announced the completion of its acquisition of Soleno Therapeutics, strengthening its endocrinology and rare disease portfolio with the addition of VYKAT XR, the first and only ...